hEGFRvIII-CD3 (BRiTE)

Phase 1Small molecule

MMustafa Khasraw, MBChB, MD, FRCP, FRACP

hEGFRvIII-CD3 (BRiTE) is one of 4 small molecule programs targeting Newly Diagnosed Glioblastoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Newly Diagnosed GlioblastomaRecruiting

Newly Diagnosed GlioblastomaPhase 1

Recruiting

Competition

Competitive Landscape

3 competitors in Newly Diagnosed Glioblastoma

#DrugCompanyPhaseTrials

Liposomal Doxorubicin

Eli Lilly

Phase 2

1 2

Balstilimab

AAgenus Inc.

Phase 2

1 3

Botensilimab

AAgenus Inc.

Phase 2

1 4

hEGFRvIII-CD3 (BRiTE)

MMustafa Khasraw, MBChB, MD, FRCP, FRACP

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

Phase 1Recruiting

Newly Diagnosed Glioblastoma

NCT04903795

Clinical

Trials by Indication[1]

Newly Diagnosed Glioblastoma1 trial

A Phase 1 Study of Bispecific T Cell Engager (BRiTE) in Patients With Newly Diagnosed or Recurrent Glioblastoma

Recruiting·MMustafa Khasraw, MBChB, MD, FRCP, FRACP·Phase 1·NCT04903795·18 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for hEGFRvIII-CD3 (BRiTE). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — hEGFRvIII-CD3 (BRiTE) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for hEGFRvIII-CD3 (BRiTE). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mustafa Khasraw, MBChB, MD, FRCP, FRACP company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: MMustafa Khasraw, MBChB, MD, FRCP, FRACP

hEGFRvIII-CD3 (BRiTE)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Newly Diagnosed Glioblastoma1 trial

References

Drug Info

Quick Facts

Related News